Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models
8.7.2025 14:30:00 CEST | ACCESS Newswire | Press Release
Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models
HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions Oncology (NASDAQ:CSBR) a leading translational oncology research organization, today announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners.
Champions now offers fully integrated radiopharmaceutical workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. The company's platform is uniquely differentiated by its extensive bank of patient-derived xenograft (PDX) tumor models, enabling drug developers to evaluate radiolabeled agents in clinically relevant systems.
"Radiopharmaceuticals represent one of the most exciting frontiers in precision oncology," said Mike Ritchie, Chief Commercial Officer at Champions Oncology. "By combining advanced radiochemistry infrastructure with the world's most deeply characterized PDX bank, we're helping our clients generate meaningful, translational data that drives confident decision-making earlier in oncology drug development."
Champions updated radioactive materials license now includes support for ten key isotopes: Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211 Tb-161, Cu-64, and Zr-89. These additions enable a wide range of study designs including radioligand therapy (RLT), antibody radionuclide conjugates (ARCs), and theranostic approaches.
"Our goal is to help biopharma partners answer critical questions faster, with data that reflects real tumor biology," continued Mike Ritchie, Chief Commercial Officer at Champions Oncology. "The integration of radionuclide workflows into our PDX platform provides a uniquely powerful preclinical toolset for evaluating biodistribution, tumor targeting, and therapeutic effect."
To learn more about Champions Oncology's radiopharmaceutical capabilities, visit:
https://www.championsoncology.com/radiopharmaceutical
About Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Contact
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
518 488 9026
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
Champions Oncology, Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Miami Fashion Week(R) Celebrates 10 Years With a Landmark Anniversary Edition, October 13-18, 20269.10.2026 17:00:00 CEST | Press Release
MIAMI, FL / ACCESS Newswire / October 9, 2026 / Miami Fashion Week® (MIAFW) celebrates its 10th anniversary this year, returning October 13-18, 2026 featuring industry programming, runway shows, and special events bringing together international designers, Latin American talent and Miami's creative community. For a decade, MIAFW has served as a bridge between Miami and the international fashion industry, creating a platform for designers while expanding beyond the runway through sustainability, technology, education and cultural exchange. The milestone edition brings together international designers, Latin American talent, fashion innovation and a new Stitch Lab retail experience Throughout these ten years, MIAFW has pioneered initiatives at the intersection of fashion, sustainability and technology. Founded in 2017, the MIAFW Summit created a space for dialogue and education around the industry's evolving challenges and opportunities. Building on that vision, the Virtual Fashion Award
IROS 2026|PaXini Showcases Full-Stack Tactile Strategy for Physical AI8.10.2026 18:15:00 CEST | Press Release
PITTSBURGH, PA / ACCESS Newswire / October 8, 2026 / As global researchers and industry leaders gathered in Pittsburgh for IROS 2026 (Sep. 27-Oct. 1) to tackle the scaling of Physical AI, PaXini AI took center stage, showcasing its full-stack products from chips to humanoid robots and hosting GEEN 2026 · IROS, the Global Embodied Ecosystem Night. The event was not merely an exchange, but an industry gathering focused on the deployment of embodied intelligence. As a leader in tactile sensing, PaXini has built a full-stack closed loop centered on touch: PIE - Perception, Intelligence, Execution. Perception enables robots to understand the real environment more comprehensively and accurately. Intelligence uses data and experience to move robots from being programmed to adapting and generalizing. Execution, through powerful actuators and dexterous end-effectors, allows robots to complete complex tasks. These three layers drive one another and form PaXini's infrastructure capability for the
Loar Holdings Inc. Announces Date and Time for Third Quarter 2026 Earnings and Conference Call7.10.2026 22:05:00 CEST | Press Release
WHITE PLAINS, NY / ACCESS Newswire / October 7, 2026 / Loar Holdings Inc. (NYSE:LOAR) will report Q3 2026 earnings before the market opens on Thursday, November 5, 2026. A conference call will follow at 11:00a.m. Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website: https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar Holdings Inc. Investor Relations IR@loa
Surmodics Launches IOL Cartridge Coating Automation Center in Horsham7.10.2026 21:30:00 CEST | Press Release
HORSHAM, PA / ACCESS Newswire / October 7, 2026 / Surmodics, a provider of surface technologies and performance coatings for the medical device industry, today announced at the opening of the American Academy of Ophthalmology annual meeting in New Orleans the launch of its IOL Cartridge Coating Automation Center at its Horsham, Pennsylvania site just outside Philadelphia. "The delivery system for an intraocular lens (IOL) combines precision injection-molded parts with a specifically selected lubricious, biofriendly coating," said Chip Hance, CEO of Surmodics. "As IOL manufacturers increasingly seek automated assembly and modern biomaterial formulations, our Automation Center provides automated coating processes designed for efficient production throughout the product lifecycle." The center brings together advanced hydrophilic coating technology, decades of IOL cartridge application expertise, precision coatings processes and automation capabilities in a manufacturing platform developed
PostSig Expands Enterprise Platform for Financial and Operational Control7.10.2026 15:00:00 CEST | Press Release
SAN FRANCISCO, CA / ACCESS Newswire / October 7, 2026 / PostSig today introduced a significant expansion of its enterprise platform, giving Finance, Procurement, Market Data and Operations teams a shared foundation for managing commercial performance. The expansion follows PostSig being named Best Data Governance Solution in WatersTechnology's 2026 Inside Market Data & Inside Reference Data Awards and its first enterprise deployment with data consultancy CJC, which manages market data for a London multi-asset broker. Pricing schedules, service orders, product inventories and entitlements change over time. When teams manage those records separately, they may see individual values but cannot reliably determine which one applies, why it changed, or how the change should affect spend. "Commercial commitments do not stop at the document," said Hendrik Bartel, CEO and Co-Founder of PostSig. "They show up in products, pricing, invoices, entitlements, usage, and accountability. PostSig connect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom